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Abstract
Stimulating naı ¨ve CD8
+ T cells with specific antigens and costimulatory signals is insufficient to induce optimal clonal
expansion and effector functions. In this study, we show that the activation and differentiation of CD8
+ T cells require IL-2
provided by activated CD4
+ T cells at the initial priming stage within 0–2.5 hours after stimulation. This critical IL-2 signal
from CD4
+ cells is mediated through the IL-2Rbc of CD8
+ cells, which is independent of IL-2Ra. The activation of IL-2
signaling advances the restriction point of the cell cycle, and thereby expedites the entry of antigen-stimulated CD8
+ T-cell
into the S phase. Besides promoting cell proliferation, IL-2 stimulation increases the amount of IFNc and granzyme B
produced by CD8
+ T cells. Furthermore, IL-2 at priming enhances the ability of P14 effector cells generated by antigen
activation to eradicate B16.gp33 tumors in vivo. Therefore, our studies demonstrate that a full CD8
+ T-cell response is
elicited by a critical temporal function of IL-2 released from CD4
+ T cells, providing mechanistic insights into the regulation
of CD8
+ T cell activation and differentiation.
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Introduction
Upon encountering their antigens, naı ¨ve T cells are activated
and driven to clonal expansion and differentiation into armed
effector cells, the cytotoxic T cells (CTL). The CTL capable of
producing cytokines and cytotoxic mediators are armed to kill
transformed, virus-infected, or allogeneic cells [1,2]. According to
the two-signal hypothesis, the induction of an optimal CD4
+ T-cell
immune response requires both antigen-specific and co-stimula-
tory signals [3,4,5]. In contrast to the CD4
+ T-cell activation,
stimulation by specific antigens and costimulatory signal fails to
drive naı ¨ve CD8
+ T cells to clonal expansion and differentiation
[6]. Thus, CD8
+ T cells require additional signals for full
activation and further differentiation into effector cells.
The role of CD4
+ T cells in CD8
+ T-cell activation has not been
fully understood. It is reported that CD8
+-mediated allograft
rejection requires CD4+ T-cell help [7] but primary CD8
+ CTL
responses to infectious agents can be readily detectable in hosts
that lack CD4
+ T cells [8,9,10]. However, these CD8
+ T-cell
primed in the absence of CD4
+ T cells are not capable of
mounting an effective secondary response [11,12], indicating that
CD4
+ T cells are required for an effective CD8
+ T-cell activation
and differentiation.
A number of models were put forth to explain how of CD4
+ T
cells help for CD8
+ T-cell responses. Studies have shown that
CD4
+ T-cell help is important for the programming of CD8
+ T-
cell differentiation [13,14,15,16]. Also, by secreting interleukin-2
(IL-2), CD4
+ T cells act at later time points to maintain CD8
+ T-
cell growth [17,18,19]. Recently, the ‘‘three-cell model’’ depicts
that CD4
+ T cells and CD8
+ T cells are brought together on the
same antigen-presenting cell (APC) for effective delivery of CD4
+
T-cell help [20,21]. CD4
+ T cells condition APCs to increase their
ability to stimulate CD8
+ T cells [20,22,23,24,25], which may
involve a direct CD40-CD40L interaction between CD4
+ and
CD8
+ cells [11]. However, several important questions remain
unanswered. First, the CD4
+ dependence of primary CTL
responses cannot be concluded firmly due to the possibility that
the primary CTL responses to non-infectious antigens are too
weak to be measured by direct ex vivo killing assays. Second, the
temporal action of CD4
+ T cells for the activation and
differentiation of CD8
+ cells remains undefined. Third, there is
controversy that some studies have found no critical role for CD40
molecules in primary or memory CD8
+ T cell responses [14,26].
Fourth, it is unknown whether the CD4
+-dependent activation of
CD8
+ T cells requires cell-cell contact or secreting mediators.
To address these issues, we hypothesized that CD4
+ T cells may
directly provide help for a CD8
+ T cell response. We adopted an in
vitro approach to dissect the cellular and molecular requirements
for CD8
+ T-cell activation and differentiation. Naı ¨ve CD62L
hiC-
D44
lo CD8
+ T cells were sorted and stimulated by anti-CD3 and
anti-CD28 antibodies. This method allowed us to study the critical
time point when CD4
+ T cells help for eliciting a CD8
+ T response
and to investigate which soluble mediator(s) is required for naı ¨ve
CD8
+ T-cell activation during priming. Here, we demonstrate that
during the early priming stage, the IL-2 produced by activated
CD4
+ T cells promotes the CD8
+ T-cell activation and
differentiation. Moreover, the IL-2 signal in priming stage
facilitates the proliferation of CD8
+ T cells by advancing the
restriction point of the cell cycle. We also showed that IL-2 at
priming enhances the ability of CD8+ T cells to eradicate tumor
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7766by producing greater quantities of interferon-c and granzyme B.
These findings takes us one step closer to the understanding of how
CD4
+ T cells help CD8
+ T-cell activation and define the temporal
function of IL-2 in regulation of a CD8
+ T cell response.
Results
IL-2 Produced by Activated CD4
+ T Cells Helps CD8
+ T-
Cell Activation
To study the requirement of naı ¨ve CD8
+ T cell activation, we
sorted CD62L
hiCD44
lo CD8
+ T cells (Figure 1A) and compared
them to splenocytes. Within 24 and 48 hours after stimulation, we
found that the CD69 and CD25 activation molecules were
significantly up-regulated in the population of splenocytes within
CD8
+ gate (Figure 1B, middle panels). However, the purified naı ¨ve
CD8
+ T cells showed poor activation under the same condition
(Figure 1B, right panels). These results suggest that factors other
than CD8
+ T-cell in the mixed splenocyte population help CD8
+
T-cell activation. To assess whether soluble mediator(s) secreted by
splenocytes plays a helper role. Supernatants collected from
cultures harvested at 0, 2, 4 and 24 hours after stimulation (0h-
Sup, 2h-Sup, 4h-Sup and 24h-Sup) were added to purified naı ¨ve
CD8
+ T cell cultures. MTT assay showed that there were
significantly more viable CD8
+ T cells in the wells containing
supernatants collected from splenocyte cultures with longer
stimulation time. These results suggest that soluble factor(s) in
the supernatant helps CD8
+ T cells to respond to stimulation
expand and survive (Figure 1C). The next question was whether
cellular factor(s), such as antigen-presenting cells (APC), plays a
helper role. We used mitomycin C-treated splenocytes as a source
of APC [27,28,29]. To avoid the soluble mediator(s) from CD4
+
cell and consider the effect of CD4
2 splenocytes, we stimulated the
naı ¨ve CD8
+ T cells in the presence of CD4-depleted splenocytes.
The results show that naı ¨ve CD8
+ T cells stimulated by anti-CD3/
CD28 antibodies in the presence of mitomycin C-treated
splenocytes or CD4
+-depleted splenocytes were only minimally
activated (Figure 1D). Thus, helper role of APC and CD4-depleted
splenocytes is limited.
To determine the cellular source of the soluble mediator(s), we
collected supernatants from purified CD4
+ T cell and from CD8
2
splenocytes cultures at 0, 2, 4, or 24 hours after anti-CD3/CD28
stimulation. Naı ¨ve CD8
+ T cells cultured in the different
supernatants were stimulated by anti-CD3/CD28 antibodies. As
demonstrated in Figure 1E and 1F, the effects of supernatants
collected from CD8
2 splenocytes and purified CD4
+ T cells were
comparable in helping CD8
+ T cell expansion and survival,
indicating that CD4
+ T cells may be the source of soluble
mediator(s). ELISA results showed that supernatants from cultures
of total splenocytes, CD8
2 splenocytes, and purified CD4
+ T cells
stimulated with anti-CD3/CD28 antibodies contained high IL-2
levels and the levels of IL-2 were comparable (Table 1). Moreover,
compared to treatment with isotype control rat IgG2a, neutralizing
IL-2 by neutralizing rat anti-murine IL-2 antibody in the culture
supernatants abolished the help provided in the culture superna-
tants to CD8
+ T cell activation (Figures 1E and 1F). These results
together suggest that IL-2 as produced by CD4 T cells is the
soluble factor that helps CD8
+ T cell activation.
IL-2 Is Critical to CD8
+ T Cell Activation at Early Time
Points during Priming
Human IL-2 binds murine IL-2 receptor to transduce IL-2
signal in murine T cells [30]. To study the effect of IL-2 in CD8
+
T-cell activation, we added human recombinant IL-2 (rhIL-2) to
naı ¨ve murine CD8
+ T cells at different time points after anti-
CD3/CD28 stimulation. While IL-2 alone did not have any effect
on CD8
+ T cells, IL-2 added between 0 to 2.5 hours after anti-
CD3/CD28 stimulation (early priming stage) resulted in greater
numbers of viable CD8
+ T cells than that added at later than
3 hours (later priming stage) (p,0.05) after stimulation (Figure 2A).
IL-2 added to 2C TCR transgenic CD8
+ T cell culture stimulated
with specific peptide QL9 at early priming stage also enhanced
antigen-specific CD8
+ T-cell expansion (Figure 2B). These results
together showed that IL-2 plays an important role during early
priming in CD8
+ T cell activation through either nonspecific anti-
CD3/CD28 or specific antigenic stimulation. Moreover, the effect
of IL-2 on CD8
+ T cell expansion was obvious at low
concentrations of nonspecific and specific antigenic stimulants
(Figure 2B and 2C) and that it had a dose-dependent effect
(Figure 2D). It is of note that lower concentrations of IL-2 added at
earlier time points had a better effect than higher concentrations at
later time points. These data showed that IL-2 exposure during
priming through TCR and costimulation pathways transduces
signal(s) critical to CD8
+ T cell activation/expansion.
The Action of IL-2 on CD8
+ T Cells Is through IL-2R
It is reported that IL-2 has an anti-apoptotic effect on activated
T cells [31,32]. To clarify whether the effect of IL-2 we observed
on CD8
+ T cell activation was a result of anti-apoptotic effect, we
compared the cell death rates between stimulated CD8
+ T cells
cultured in the presence and absence of rhIL-2. Flow cytometric
analysis showed that there was no significant difference in the
percentage of cell death between these two groups at 3.5, 12 and
24 hours after stimulation (Table 2). The cells kept at 4uC were
used as negative control. Since rhIL-2 added between 0 to
2.5 hours after anti-CD3/CD28 stimulation (early priming stage)
resulted in greater numbers of viable CD8
+ T cells than that added
at later than 3 hours (later priming stage) (p,0.05) after
stimulation (Figure 2A), the effect of rhIL-2 at early priming of
CD8
+ T cell activation may not be through an anti-apoptotic
mechanism.
To exclude the possibility that the effect of IL-2 signaling on
CD8
+ T-cells is triggering greater production of IL-2, we added
rhIL-2 to naı ¨ve CD8
+ T cell culture and determined the
concentrations of murine IL-2 in the culture supernatants at 24
(Figure 3A, left panel) and 48 hours (Figure 3A, right panel) after
stimulation. Figures 3A shows that exogenous rhIL-2 did not
induce stimulated CD8
+ T cells to produce more murine IL-2
whenever addition at 0 hour or 24 hours after stimulation. We
have found that IL-2 signal at early priming triggers CD8
+ T-cells
expansion (Figure 2A). Thus, to further check whether the cells
expansion is induced by IL-2 production from the anit-CD3/
CD28- and rhIL-2- activated CD8
+ T-cells, we added anti-murine
IL-2 antibody to neutralize endogenous murine IL-2. The results
showed neutralization of murine IL-2 did not ablate the effect of
rhIL-2 on CD8
+ T-cell viability at 72 hours after stimulation
(Figures 3B), demonstrating that the function of exogenous IL-2 is
not to induce more murine IL-2 production.
It has been reported that upon stimulation, the a-chain of IL-2
receptor (IL-2Ra, CD25) is induced and associates with IL-2Rb
(CD122) and IL-2Rc (CD132) to form a high-affinity receptor
[33]. To determine whether IL-2 at priming induces the up-
regulation of IL-2 receptor subunits, we harvested CD8
+ T cells at
different time points after stimulation by anti-CD3/CD28
antibodies and analyzed CD25 expression by flow cytometry.
We found that surface CD25 expression was induced at as early as
4 hours and IL-2 further up-regulated its expression at 6, 12 and
24 hours after stimulation (Figure 3C). Interestingly, IL-2 receptor
b-chain expression was not altered by IL-2 (Figure 3D). Since the
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PLoS ONE | www.plosone.org 2 November 2009 | Volume 4 | Issue 11 | e7766Figure 1. Activated CD4
+ T cells secreted IL-2 to help primary CD8
+ T-cell activation. (A) Naı ¨ve CD8
+ T cells (CD62L
hiCD44
lo) from B6 mice
spleen with purity above 93% were obtained through B cell depletion, CD8
+ T cells enrichment by panning and further enriched by MACS sorting
with anti-CD62L MACS beads. (B) Expression of activation markers, CD69 and CD25. 3610
6/mL of naı ¨ve CD8
+ T cells (left) were stimulated by anti-
CD3/CD28 antibodies for 0 hour and splenocytes (middle) or naı ¨ve CD8
+ T cells (right) in 24-well culture plate were stimulated by anti-CD3/CD28
antibodies for indicated time, 24 and 48 hours and harvested, followed by staining with FITC anti-CD25, PE anti-CD69 and PE-Cy5 anti-CD8
antibodies, and analysis by flow cytometry. Dotted line: Isotype control. (C) Naı ¨ve CD8
+ T cells (1610
5/well) in a 96-well culture plate were stimulated
in the presence or absence of mitomycin C-treated splenocytes (APC) for 96 hours, followed by MTT assay (numbers represent OD at 570 nm). The
effect of CD4-depleted splenocytes was also checked (#). (D) Culture supernatants of anti-CD3/CD28 stimulated splenocytes for the indicated time, 0,
2, 4 and 24 hours (0 h-, 2 h-, 4 h- and 24 h-Sup) were collected. Naı ¨ve CD8
+ T cells (3610
5/well) in the 96-well culture plate were then incubated with
the culture supernatant with (&) or without (%) stimulation by anti-CD3/CD28 antibodies. Following 96 hours of stimulation, the cell viability was
measured by MTT assay. (E and F) Naı ¨ve CD8
+ T cells (3610
5/well) in the 96-well culture plate were stimulated in the presence of culture supernatants
of 0 h-, 2 h-, 4 h- and 24 h-stimulated CD8
2 splenocytes (E) or 0 h-, 2 h-, 4 h- and 24 h-stimulated CD4
+ T cells (F) for 96 hours. Anti-mouse IL-2
antibody (2.5 mg/mL) was used to neutralize murine IL-2 in culture supernatant. The cell viability was measured by MTT assay. The data represent
three independent experiments. #, The groups in which the cells received anti-IL-2 or isotype control antibody were not included. *, **, significantly
statistical difference by student t-test, p,0.05. APC, antigen-presenting cells. CD8
2, CD8
+-depleted splenocytes. Spl, splenocytes. Sup, culture
supernatant. Ab, antibody. Ctrl, isotype control of rat anti-murine IL-2 antibody, rat IgG2a.
doi:10.1371/journal.pone.0007766.g001
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+ T cell expansion was most effective during
the first 2.5 hours after stimulation (Figure 2A), CD25 up-
regulation may not be responsible for the IL-2 signal in early
priming stage.
Naı ¨ve CD8
+ T cells bear intermediate-affinity receptor (IL-
2Rbc) for IL-2 [34]. IL-2 is known to regulate T cell function by
activating transcription factor STAT5 [35]. To investigate
whether IL-2 transduces signals through intermediate-affinity
receptor IL-2Rbc during CD8
+ T cell priming, we stimulated
naı ¨ve CD8
+ T cells and studied the phosphorylation of STAT5
after stimulation. Figure 3E demonstrates that exposure to IL-2
induced CD8
+ T cell STAT5 phosphorylation and the effect of IL-
Table 1. IL-2 concentration in culture supernatants of
stimulated splenocytes, CD8-depleted splenocytes and
purified CD4
+ T cells.
Time from
stimulation (h) IL-2 concentration (pg/mL)
splenocytes CD8
2 splenocytes CD4
+ cells
0 N.D.* N.D.* N.D.*
2 16.5 14.1 26.7
4 222.9 140.3 435.3
6 972.3 873.8 662.2
24 8167.9 7553.3 11841.2
*N.D., not detectable.
doi:10.1371/journal.pone.0007766.t001
Figure 2. The time and amount of IL-2 required for promoting CD8
+ T-cell activation. (A) Recombinant human IL-2 (rhIL-2, 5 ng/mL) was
administrated at indicated time following CD8
+ T-cell stimulation by anti-CD3/CD28 antibodies. Following 96 hours, cell viability was measured by
MTT assay at absorbance of 570 nm (&). The cells were incubated with rhIL-2 alone as control (%). (B) In the presence (#) or absence (&) of rhIL-2 in
priming stage, naive CD8
+ T cells from 2C TCR transgenic mice were stimulated with specific peptide, QL9 in titrations for 96 hours, followed by MTT
assay. (C) In the presence (N) or absence (&) of rhIL-2 in priming stage, naı ¨ve B6 CD8
+ T cells were stimulated by anti-CD3 in titrated concentrations
for 96 hours, followed by MTT assay. (D) rhIL-2 in titrated concentrations, 5, 0.5 or 0.05 ng/mL was administered to the CD8
+ T cells at 0 (&), 12 (N)
and 24 (m) hours after stimulation by anti-CD3/CD28 antibodies. The cells were incubated with rhIL-2 alone as controls. Following 96 hours, cell
viability was measured by MTT assay. The data represent three independent experiments. *, significantly statistical difference by student t-test,
p,0.05.
doi:10.1371/journal.pone.0007766.g002
Table 2. Rate of Annexin V positive in CD8
+ T cells under
various stimulation.
Positive Annexin V (%)
Time from
stimulation (h)
aCD3/
CD28
aCD3/
CD28+IL-2 IL-2
Cells kept
at 4uC
3.5 41 37 40 15
12 54 54 51 22
24 62 61 67 30
doi:10.1371/journal.pone.0007766.t002
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PLoS ONE | www.plosone.org 4 November 2009 | Volume 4 | Issue 11 | e7766Figure 3. IL-2 signals to naı ¨ve CD8
+ T cells through IL2R. (A) Naı ¨ve CD8
+ T cells (3610
6/mL) were stimulated by anti-CD3/CD28 antibodies in
the presence or absence of rhIL-2 at priming (0 hour) or 24 hours after priming. At 24 (left) and 48 (right) hours following stimulation, murine IL-2
level in culture supernatant was checked by ELISA. The culture supernatant of 24 hours-stimulated splenocytes was used as positive control. (B)
Neutralizing anti-mouse IL-2 (2.5 mg/mL) was added simultaneously with rhIL-2 (5 ng/mL) upon the naı ¨ve CD8
+ T cell stimulation, followed by MTT
assay 72 hours after stimulation. (C and D) At indicated time, 2, 4, 6, 12 and 24 hours following stimulation by anti-CD3/CD28 antibodies, CD8
+ T cells
were harvested and stained by FITC anti-mouse CD25 (C) or FITC anti-mouse CD122 (D) antibody and analyzed by flow cytometry (Solid line). Dotted
line: Isotype control. Gray filled: Naı ¨ve CD8
+ T cells. The percent of cells which have CD25 or CD122 expression in the population and mean
fluorescence intensity (MFI) were shown. (E) Following stimulation for 120 min, phospho-stat5 was analyzed by Western blotting. rhIL-2 (5 ng/mL)
and blocking anti-CD122 (20 mg/mL) were added. Positive control: Hela cells treated by IFNa. Negative control: Hela cells without treatment. (F)
Blocking anti-CD122 antibody and isotype control rat IgG2b (#) was administered simultaneously with rhIL-2 to naı ¨ve CD8
+ T cells upon stimulation
by anti-CD3/CD28 antibodies, followed by MTT assay 96 hours after stimulation. Similar results were obtained in three independent experiments. The
data represent three independent experiments. *, significantly statistical difference by student t-test, p,0.05. Ctrl, control.
doi:10.1371/journal.pone.0007766.g003
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blocking CD122 also impeded CD8
+ T cell expansion (Figure 3F).
Taken together, these results indicate that at the priming stage of
CD8
+ T cell activation, IL-2 delivers a functional signal through
IL-2Rbc that is independent of IL-2Ra.
IL-2 Signaling Advances CD8
+ T Cells through S Phase
and Accelerates the Cells Entering Cell Cycle
We hypothesized that IL-2 may help CD8
+ T cell activation
through enhancing the signal that drives proliferation. To test this
hypothesis, we monitored cell numbers on a daily basis for four
consecutive days. Figure 4A shows that CD8
+ T cell number was
4-fold higher in the group treated with IL-2 than that without IL-2
at 3 days after anti-CD3/CD28-stimulation. The results of CFSE
analysis showed that CD8
+ T cells cultured in the presence of
exogenous IL-2 divided more vigorously than those in the absence
of IL-2 (Figure 4B). To study whether greater number of cell
division is due to higher number of cells entering cell cycle, we
used BrdU incorporation assay to assess the number of cells
entering the S phase, the restriction point, of cell cycle. Results in
Figure 4C show that it took 48 hours after stimulation for 50% of
CD8
+ T cells cultured in the absence of IL-2 to enter S phase and
addition of IL-2 reduced the time to enter S phase to 36 hours. We
then examined the expression of cell cycle-regulatory proteins,
p19, p27, cyclins A, D1 and E. Western blots in Figure 4D show
that anti-CD3/CD28 stimulation down-regulated p27 protein.
The results also showed that stimulation in the presence of IL-2
further up-regulated cyclins A, D1 and E, but not p19. The
chemical (N9-((4-Oxo-4H-chromen-3-yl)methylene) nicoti-
nohydrazide) has been shown to block STAT5/STAT5 DNA
binding activity and inhibit STAT5 tyrosine phosphorylation [35].
We further checked the Cyclin E protein expression after
administration of the STAT5 inhibitor to the anti-CD3/CD28-
and IL-2-stimulated CD8
+ T cells. The results revealed that the
amount of Cyclin E protein of stimulated CD8
+ T cells was
diminished upon treatment with STAT5 inhibitor, indicating the
up-regulated expression of Cyclin E protein by IL-2 signals is
dependent on the phosphorylation of STAT5 (Figure 4E). These
data suggest that IL-2 helps CD8
+ T cell activation by up-
regulating cyclins A, D1 and E and down-regulating p27.
IL-2 Signaling during Priming Helps CD8
+ T Cells
Acquiring Effector Functions
To determine whether IL-2 helps CD8
+ T cells to acquire
effector functions, we examined their IFNc, granzyme B and
perforin productions after priming. Figure 5A shows that CD8
+ T
cells stimulated in the presence of IL-2 produced higher
concentrations of IFNc than those without IL-2 treatment, and
IL-2 added at 0 hour of stimulation had greater effect on IFNc
production than that added at 24 hours after stimulation.
Moreover, there were a higher percentage of IFNc-producing
cells in the culture with IL-2 added at 0 hour of stimulation
(Figure 5B). IL-2 treatment also increased the percentage of
granzyme B-producing cells in the CD8
+ T cell population
(Figure 5C). Yet, the level of perforin expression was not increased
in cells with IL-2 treatment (Figure 5D). These data together
indicate that IL-2 signaling during priming helps CD8
+ T cells
acquire effector functions.
Generation of Potent CD8
+ T Cell Anti-Tumor Effector
Function Depends upon IL-2 Help
To assess whether the IL-2 signal in vitro at CD8
+ T-cell priming
may enhance CTL activity in vivo, we adoptively transferred
activated P14 effector T cells of which the T-cell receptor is
specific for MHC class I-restricted GP33 epitope of lymphocytic
choriomeningitis virus (LCMV). The P14 CD8
+ effector cells
which were generated by in vitro stimulation with the specific
peptide, KM9 (KAVTNFATM) in the presence (P14IL-2)o r
absence (P14) of IL-2. The P14IL-2 or P14 T effector cells were
then adoptively transferred to B16-F10 or B16.gp33 melanoma-
bearing mice at 8 days after tumor cell inoculation (Figure 6A). At
11 days after tumor cell inoculation, the lungs were removed and
shown in figure 6B. And, the number and the size of melanoma
nodules in lungs were recorded. The results showed that adoptive
transfer of P14 T effector cells treated with IL-2 at 0 hour after
peptide stimulation (P14IL-2 (0 h)) caused a significant reduction in
the number (Figure 6C, left panel) and the size (Figure 6D) of
pulmonary nodules compared to transfer of P14 T cells treated
with IL-2 starting at 24 hours (P14IL-2 (24 h)) after peptide
stimulation and that without IL-2 treatment (P14). While, transfer
of the effector cells did not show tumor elimination in B16.F10-
bearing mice (Figure 6C, right panel).
H & E stain revealed that there were lymphocytes migrating out
of the circulation to tumor sites in mice receiving effector T cells at
one day after adoptive transfer (Figure 6E). Of note, more
lymphocytes infiltrated into the tumor sites in the mice receiving
P14IL-2 (0 h) T cells than that in mice receiving P14 (Figure 6F).
Apoptotic bodies were also found in the tumor (Figure 6F, arrow).
To test the hypothesis that the more potent tumor eradication
in mice receiving P14IL-2 (0 h) effector cells is caused by greater
cytolytic function of the cells transferred, we checked the
production of granzyme B and IFNc of the tumor-infiltrating
lymphocytes of effector cells. At 4 hours after effector cells
transferred, the lung was resected and stained with anti-Granzyme
B and anti-IFNc antibodies by immunohistochemical staining
(Figure 7A and 7B, upper panel). The results showed that there
were more Granzyme B- and IFNc- producing cells in the tumor
in mice receiving P14IL-2 (0 h) than other groups. We also labeled
the effector cells with CFSE before transfer and isolated the
lymphocytes in the lung. The expression of granzyme B and IFNc
of the CFSE-labeled cells were then checked by intracellular
staining and analyzed by flow cytometry (Figure 7A and 7B, lower
panel). We found that greater percentage of tumor-infiltrating
P14IL-2 (0 h) effector T cells produced granzyme B and IFNc than
P14 and P14IL-2 (24 h) effector T cells (granzyme B: 47.13% vs.
18.59% vs. 30.73%, IFNc: 35.26% vs. 27.29% vs. 27.26%). These
results demonstrate that P14 effector T cells generated in the
presence of IL-2 from 0 h on attained better effector function and
were highly effective in reducing tumor burden in vivo. Exposing
P14 T cells to IL-2 at later time point (24 hours after stimulation)
during peptide stimulation generated P14 effector T cells with only
moderate therapeutic efficacy in vivo. It clearly indicates that IL-2
exposure and the temporal function of IL-2 during TCR
stimulation control the potency of the CD8
+ effector T cells
generated.
Discussion
CD8
+ T cells are key effector cells to fight against tumor
and viral infections. It is crucial that CD8
+ T cells proceed to
undergo expansion and acquire full effector functions upon
activation through specific T cell receptor and costimulatory
molecules. Previous studies have shown that CD4
+ T-cell help is
required for the generation of functional CD8
+ T-cell responses
[13,14,15,18,23,24,25]. However, it is not clear at what point
during CD8
+ T cell priming that CD4
+ T-cell help is needed. This
paper describes our findings on the timing and how CD4
+ T cells
IL-2 Helps CD8
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PLoS ONE | www.plosone.org 6 November 2009 | Volume 4 | Issue 11 | e7766Figure 4. Regulation of cell cycle by IL-2 signals at priming. (A) In the presence (N) or absence (&) of rhIL-2 (5 ng/mL) at priming, the anti-
CD3/CD28-stimulated CD8
+ T cells were counted day by day (left). Folds increase was determined day by day (right). (B) In the presence or absence of
rhIL-2 at priming, CFSE-labeled naı ¨ve CD8
+ T cells were stimulated by anti-CD3/CD28 antibodies for indicated time, 24, 48 and 72 hours, and cell
divisions were analyzed by flow cytometry (black filled). Gray filled: CFSE-labeled naı ¨ve CD8
+ T cells. (C) Naı ¨ve CD8
+ T cells were stimulated by anti-
CD3/CD28 antibodies for the indicated time, 0, 24, 36 and 48 hours, and analyzed by flow cytometry for the BrdU incorporation to determine the
percentage of cell entering S phase (Solid line). Cells stimulated by anti-CD3/CD28 antibodies also with rmIL-2 administration at priming were shown
as a dotted line. Dashed line shows cells additionally treated by rmIL-2 and anti-mouse IL-2 at priming. R and R’ stands for restriction point. (D) Total
cell extracts of 1.5610
6 CD8
+ T cells at 18 hours after stimulation were collected for further Immunoblotting with antibodies against cyclins A, D1 and
E, p19, p27 and actin, respectively. IL-2 (5 ng/mL) was added at priming. The data represent three independent experiments. (D = day)
doi:10.1371/journal.pone.0007766.g004
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+ T-cell differentiation. (A) At 48 hours after anti-CD3/CD28 antibodies stimulation, IFNc level
was checked by ELISA. Naı ¨ve CD8
+ T cells were stimulated by anti-CD3/CD28 in the presence or absence of rhIL-2 (5 ng/mL and 0.5 ng/mL) treatment
at 0 hour and 24 hours, respectively. (B) At 24 and 48 hours after anti-CD3/CD28 stimulation, production of IFNc in CD8
+ T cells was checked by
intracellular staining and analyzed by flow cytometry. rhIL-2 (5 ng/mL) was added at 0, 12 and 24 hours after stimulation, respectively. Percentage of
IFNc-producing cells was shown. (C) At 48 hours after anti-CD3/CD28 stimulation, granzyme B production was checked by intracellular staining and
analyzed by flow cytometry. Percentage of granzyme B-producing cells was shown. (D) At 24 hours after anti-CD3/CD28 stimulation, perforin
production was checked by intracellular staining and analyzed by flow cytometry. Percentage of perforin-producing cells was shown. Similar results
were obtained in three independent experiments.
doi:10.1371/journal.pone.0007766.g005
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+ T-cell priming may enhance better tumor-eradicating efficacy in vivo. (A) B16-F10 or B16.gp33
melanoma cells were inoculated intravenously into host mice (0.5610
6 cells per mouse), followed by injection of P14 effector T cells (1610
7 cells per
mouse) at 8 days after the tumor injection. The mice were sacrificed one day later for pathology study of lung nodules, or three days later for
checking lung tumor nodules. (B) Three days after P14 effector cells transfer, the lungs of two mice in each group was shown. (C) Three days after P14
effector cells transfer, the number of B16.gp33 (left) and B16-F10 (right) melanoma colonies in lung was recorded. (D) Three days after P14 effector
cells transfer, the size of B16.gp33 melanoma colonies in lung was recorded. (E and F) One day after P14 effector cells transfer, the lung was fixed in
formalin, followed by H& E staining. The pathology of lung nodules was visualized by microscopy at 1006(E) and 4006(F) of magnification. w/o
transfer, without cell transfer. P14, transfer with P14 CD8
+ T effector cells in absence of IL-2 at priming, P14IL-2 (0 h) and P14IL-2 (24 h) in presence of IL-
2 at 0 hour and 24 hours after stimulation, respectively. Similar results were obtained in three independent experiments. *, **, significantly statistical
difference by student t- test, p,0.05. Arrow in (E), lymphocytes. Arrow in (F), apoptotic body.
doi:10.1371/journal.pone.0007766.g006
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+ T cells that result in functionally activated
effector cells.
We showed that by secreting IL-2, activated CD4
+ T cells
provide help to CD8
+ T cells. It was the signals transduced
through IL-2Rbc within the first 0–2.5 hours that IL-2 helps
CD8
+ T cell activation. The activation of IL-2 signaling
advances the restriction point of cell cycle, and thereby expedites
the entry of stimulated CD8
+ T cells into the S phase. Besides
promoting CD8
+ T cells proliferation, IL-2 stimulation also
augments IFNc and granzyme B production. Importantly,
effector CD8
+ T cells generated in vitro i nt h ep r e s e n c eo fI L - 2
at the priming stage proved to be fully functional in anti-tumor
activity in vivo.A sar e s u l t ,C D 4
+ T-cell help represents a
‘checkpoint’ in triggering a CD8
+ T-cell response and insures a
productive CD8
+ T-cell response occurs only under appropriate
circumstances. Our work demonstrated the temporal function of
CD4
+ T cell-derived IL-2 for governing the activation and
differentiation of CD8
+ T cells.
Figure 7. IL-2 signal at priming drove better anti-tumor CTL function in vivo. (A) Expression of granzyme B in tumor-infiltrating
lymphocytes. Upper panel. At 4 hours after effector cells transfer, the lung tissue was subjected to immunohistochemical staining by FITC anti-
granzyme B antibody (1 mg/mL), followed by anti-Fluorescein peroxidase. After wash, the tissue was subjected to NOVA-RED and Hematoxylin
staining. Lower panel. At 4 hours after transfer of CFSE-labeled effector cells, the lymphocytes in the lung were isolated and subjected to intracellular
staining by PE anti-granzyme B antibody, and analysis by flow cytometry. (B) Expression of IFNc in tumor-infiltrating lymphocytes. Upper panel.A t
4 hours after effector cells transfer, the IFNc production in the lung was checked by immunohistochemical staining by anti-IFNc antibody (5 mg/mL),
followed by biotin goat anti-rat Ig (1 mg/mL) and streptavidin-peroxidase (1:1000). After wash, the tissue was subjected to NOVA-RED and
Hematoxylin staining. Lower panel. As (A), the production of IFNc was also checked in the CFSE-labeled effector cells using intracellular staining by PE
anti-IFNc antibody, and analysis by flow cytometry. Similar results were obtained in three independent experiments.
doi:10.1371/journal.pone.0007766.g007
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decades that IL-2 not only serves as a growth factor for T cells
following activation [18,19], but also prevents T cells from anergy
[36,37]. One recent study showed that IL-2 signals to pathogen-
specific CD8
+ T cells during primary infection are crucial for the
generation of robust secondary expansion of CD8
+ memory T cells
[38]. However, less is known how it acts to shape the CD8
+ T-cell
response in priming phase. One recent report has shown that naive
CD8
+ T cells preferentially accumulated in lymph nodes and
attracted to the sites of antigen-specific dendritic cell-CD4
+ T cell
interaction. Thus, the naı ¨ve CD8
+ T cells were kept in close
proximity to activated CD4
+ T cells. This allows the immune
system to efficiently activate the naı ¨ve CD8
+ T cells [39]. Our study
and other reports showed that CD4
+ T cells secret significant
amount of IL-2 soon immediately after activation (Table 1) [40,41].
It is plausible for naı ¨ve CD8
+ T cells to expose to a high
concentration of IL-2 locally when they are encountering the
specific antigen. It is noteworthy that naı ¨ve CD8
+ T cells only bear
IL-2Rbc, the intermediate affinity receptor for IL-2 [33] and the a-
chain of IL-2 receptor, CD25, is not expressed on naı ¨ve CD8
+ T
cells and is significantly up-regulated until 6 hours after stimulation
(Figure 3E). It is plausible that IL-2 at priming delivers a functional
signal through IL-2Rbc to up-regulate CD25 expression, which
further ensures the antigen-stimulated CD8
+ T-cell proliferation.
We also showed that IL-2 alone was not able to initiate CD8
+
T-cell proliferation, and to elicit a full activation of CD8
+ T cells
occurs only when antigen is present. Activation of the TCR
renders the cells ‘‘competent’’ to receive the cell-cycle progression
signals that are provided by IL-2. Once IL-2 signals at CD8
+ T-
cells priming is transduced, the cell cycle-governing proteins such
as cyclin A, cyclin D1, and cyclin E are up-regulated. In this
respect, antigen-stimulated cells which undergo G0 to G1
transition can thus progress through G1 to S phase without delay
when IL-2 is also provided. However, when IL-2 is provided at
later time, the cells may require more time to enter S phase. Or,
the cells may be arrested until later production of autocrine IL-2 to
precede the process. Furthermore, IL-2 at priming also induces
up-regulation of CD25 expression, which further ensures the
signal transduction of IL-2 in the antigen-stimulated CD8
+ T-cells.
Not only the impact on cell cycle, IL-2 provided at early priming
also enhanced CD8
+ T cells effector function. The production of
IFNc from activated CD8
+ T cells increased at 48 hours after
stimulation whenever IL-2 added at early or later time. But the
concentration of IFNc from CD8
+ T cells added IL-2 at 24 hours
after stimulation was not as high as that in IL-2 added at 0 hour
(Figure 5A). And, IL-2 added at early priming rendered more
IFNc–producing cells in the population. However, the percentage
of IFNc–producing cells did not increase significantly at 48 hours
later when IL-2 provided at 12 or 24 hours after stimulation
(Figure 5B). These suggest that IL-2 signals at early priming may
expedite the CD8
+ T cells to attain full differentiation.
Accordingly, the antigen-stimulated CD8
+ T-cells with later IL-2
administration may need longer time to produce higher amount of
IFNc than that IL-2 added at early priming (Figure 5A and B).
The similar pattern was also shown in Granzyme B-producing
activated CD8
+ T cells (Figure 5C) but not in perforin-producing
cells (Figure 5D). Taken together, when encountering their
antigen, the IL-2 signals at priming not only ensure the antigen-
stimulated CD8
+ T cells to progress the cell cycle, but may also
advances the response faster. Therefore, the present study suggests
that the temporal function of IL-2 signal is critical for the antigen-
stimulated CD8+ T cells to attain a full activation.
T-cell adoptive immunotherapy is a treatment strategy for
cancer. Despite the fact that a coordinated effort by modifications
in culture technique and administration of nonmyeloablative
chemotherapy has markedly improved of the clinical response in
melanoma patients, it remains poorly understood why the tumor
regression tend to be partial. To achieve the best therapeutic
efficacy, it is crucial to adoptive transfer the CTL with good
effector function. Our data showed that IL-2 signal at priming
stage in vitro drove development of CD8
+ effector cells which
produced greater quantities of IFNc and Granzyme B when
encountered the tumor in vivo. The more tumor-infiltrating
lymphocytes were also observed in the group of IL-2 adding at
priming. The results reported here demonstrate that IL-2 signal in
the early priming stage not only drove the CD8
+ T-cell
differentiation but also aid to maintain effector function in vivo.
On the basis of the findings of this study, the requirement of
CD4
+ T-cell help for regulation of CD8
+ T-cell immune responses
should be reconsidered more precisely. It is speculated that
following activation, CD4
+ T cells secrete IL-2 to directly help
CD8
+ T-cell priming. As a consequence, the antigen-stimulated
CD8
+ T cells attain full activation and differentiation. It reflects
that CD4
+ T-cell help promotes a net gain of stimulation for those
neighboring CD8
+ T cells. Interestingly, IL-2 signals exclusively to
antigen-encountered CD8
+ T cells also confine the immune
response in local inflammatory sites. As a result, undesired
systemic immune responses can be limited. Elucidation of the
mechanism will aid to better understand the development of CD8
+
T-cell activation and differentiation and to optimize vaccine
strategies for inducing protective immunity.
Materials and Methods
Mice
All procedures were performed following the guideline of the
Use of Laboratory Animals published by National Taiwan
University and approved by Institutional Animal Care and Use
Committee of College of Medicine and College of Public Health of
National Taiwan University. C57BL/6 mice were obtained from
the animal center at National Taiwan University Hospital and
maintained in pathogen-free conditions. The 2C and P14 TCR-
transgenic mice were kindly obtained from Dr. John T. Kung
(Academia Sinica, Taipei, Taiwan). 2C transgenic mice carries
functional rearranged TCR a-(one copy) and b-(eight copies)
chain transgenes from a cytotoxic T-cell clone 2C which is specific
for L
d MHC class I antigen. P14 transgenic mice carries
rearranged TCR transgenes specific for the gp33 epitope (amino
acid 33–41 of glycoprotein) of lymphocytic choriomeningitis virus
(LCMV). All animals were maintained in the specific pathogen-
free facility and were used at age of 4–6 weeks.
Cell Preparation and Culture Conditions
Cells. Naı ¨ve CD62L
hiCD44
loCD8
+ T cells used for
experiments were obtained from spleens of either C57BL/6
mice or 2C TCR-transgenic mice specific for QL9 peptide.
Isolation of naı ¨ve CD8
+ T cells. Single-cell splenocytes
suspensions were twice depleted of Ig
+ B cells by adherence to
culture plates coated with anti-Igm mAb and anti-Igk mAb for
60 min at room temperature. Nonadherent cells were collected
and CD8
+ T cells with purity above 95% were enriched by
incubated in anti-CD8 mAb (clone 3.155)-coated culture plates.
CD62L
hi cells were then positively isolated by magnetic cell
sorting. The resultant CD8
+CD62L
hiCD44
low T cells with purity
above 93% were used for further experiments.
Isolation of naı ¨ve CD8
2 splenocytes. Single-cell
splenocytes suspensions were twice depleted of CD8
+ T cells by
adherence to culture plates collated with anti-CD8 mAb (clone
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were collected and less than 0.5% of CD8
+ T cells were detected in
the cell populations.
Isolation of CD4
+ T cells. Single-cell splenocytes
suspensions were twice depleted of Ig
+ B cells by adherence to
culture plates coated with anti-Igm mAb and anti-Igk mAb for
60 min at room temperature. Nonadherent cells were collected
and CD4
+ T cells with purity above 95% were enriched by
incubated in anti-CD4 mAb (clone GK1.5)-coated culture plates.
Primary CD8
+ T cell stimulation. All naı ¨ve CD8
+ T cells
activation cultures were set up in DMEM containing 10% FBS,
50 mM HEPES and 5610
25 M 2-ME in standard 24- or 96-well
microculture plates (Corning Inc.). To activate T cells, the naı ¨ve
CD8
+ T cells were incubated in 96- or 24-well plate in the
presence of 1 mg/mL rabbit anti-hamster (R anti-H) plus anti-
CD3 mAb (clone 145-2C11) and anti-CD28 mAb (clone PV1) for
the indicated time. For activating 2C transgenic CD8
+ T cells, the
cells were incubated with mitomycin C-treated (inhibition of DNA
synthesis) [27,28,29] LPS-stimulated B blasts [42,43] from B10.A
mice and QL9 peptide (QLSPFPFDL, Proimmune Inc., Oxford,
United Kingdom) in titrated concentrations. Recombinant murine
IL-2 and recombinant human IL-2 were administrated at a final
concentration of 5 ng/mL (equivalent to 100 IU/mL). Cell
numbers were determined by trypan blue exclusion. Cells were
grown at 37uC and 5% CO2 in humidified air.
Collection of Culture Supernatants
Total splenocytes, CD8
2 splenocytes and CD4
+ T cells were
stimulated by immobilized anti-CD3 plus soluble R anti-H and
anti-CD28 antibodies for indicated time, 0, 2, 4 and 24 hours. The
culture supernatants were collected for further experiments.
Antibodies and Reagents
DMEM and penicillin and streptomycin from GIBCO
Inc.(Grand Island, NY, USA), and Fetal bovine serum (FBS) from
HyClone Lab Inc.(Logan, UT, USA) were purchased. Hamster
anti-mouse CD3 monoclonal antibody (clone 145-2C11), hamster
anti-mouse CD28 monoclonal antibody (clone PV1), rat anti-
mouse CD4 monoclonal antibody (clone GK1.5) were prepared in
our laboratory. Anti-mouse Igm (clone Bet.2) and anti-mouse Igk
(clone 187.1) and rat anti-mouse CD8 monoclonal antibodies
(clone 3.155) were gifts from Dr. John T. Kung (Academia Sinica,
Taipei, Taiwan). Anti-mouse IL-2 antibody (clone S4B6), isotype
control rat IgG2a, anti-mouse IFNc (clone XMG1.2), FITC anti-
mouse granzyme B (clone 16G6), PE anti-mouse perforin (clone
eBioOMAK-D, eBioscience, San Diego, CA, USA), FITC anti-
mouse CD3, PE anti-mouse CD4, PE-Cy5 anti-mouse CD8,
FITC anti-mouse CD25, PE anti-mouse CD69, FITC anti-
CD122, FITC Annexin V, mouse anti–p27 antibodies and BrdU
kit (BD Pharmingen, San Diego, CA, USA), rat anti-CD122
antibody (TM-b1) and isotype control rat IgG2b (eBioscience, San
Diego, CA, USA), rabbit polyclonal anti-HIg antibody (R anti-H,
Jackson ImmunoResearch Laboratories, West Grove, PA, USA),
mouse anti-cyclin E antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), mouse anti-actin (Chemicon, Temecula, CA,
USA) were used in the experiments. MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide), mitomycin C and propi-
dium iodide (Sigma, St Louis, MO, USA) were purchased. Anti-
phospho-stat5 and anti-stat5 antibodies were purchased from Cell
Signaling Technology, Inc. (Danvers, MA, USA). Goat polyclonal
anti-rabbit and anti–mouse IgG–horseradish peroxidase were
purchased from Amershan Corp (Little Chalfont, Buckingham-
shire, United Kingdom).
Cell Proliferation Assays
MTT assay (colorimetric assay). MTT is especially useful
for assaying the quantification of viable cells, because MTT is
cleaved to form a formazan dye (purple color) only by metabolic
active cells [44,45,46]. Following stimulation for 96 hours, the cells
were incubated with MTT (1 mg/mL) for another 4 hours. The
formazan was solubilized by dimethyl sulfoxide and colorimetric
absorbance was quantified by measuring the optical density (OD)
at 570 nm by a spectrophotometer (Tecan Group Ltd.,
Ma ¨nnedorf, Switzerland).
CFSE (carboxyfluorescein succinimidyl ester)
labeling. Before stimulation, the naı ¨ve CD8
+ T cells were
resuspended at a concentration of 10610
6 cells/mL in 0.1%
bovine serum albumin (BSA) in PBS and CFSE (Molecular
Probes, Eugene, OR, USA) was added to a final concentration of
5 mM. After 10 min of incubation at 37uC, labeling was quenched
with ice-cold DMEM. Cells were washed and resuspended in
DMEM for further culture. At the indicated time following
stimulation, the cells were analyzed by flow cytometry.
BrdU incorporation. BrdU (10 mM) was added to cell
cultures during the final 60 min. Cells were harvested and fixed
and resuspended in DNase I solution as described [47]. To stain
BrdU, FITC anti-BrdU antibody (1 mg/mL) was used for 30 min
at 4uC and washed by FACS buffer (2% FBS in 1X PBS). The cells
were analyzed by flow cytometry.
Expression of Cyclins and STAT 5 Inhibition
The naı ¨ve CD8
+ T cells were incubated with anti-CD3/CD28
antibodies in the presence of absence of rhIL-2 (5 ng/mL). At the
indicated time, 18 and 24 hours after stimulation, the cells were
lysed with modified RIPA solution (50 mM tris-HCl [pH 7.4],
150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% Na-deoxycho-
late, 1 mM PMSF, 1 mM orthovanadate and 0.1% SDS) with a
protease inhibitor cocktail (Roche, Mannheim, Germany) [48] and
20 mg of the protein was subjected to SDS PAGE, followed by
immunoblotting. To inhibit stat5 phosphorylation, the cells were
pretreated with the stat5 inhibitor (N9-((4-Oxo-4H-chromen-3-
yl)methylene) nicotinohydrazide, Calbiochem Inc.) [35] in titrated
concentrations for 15 minutes, followed by stimulation with anti-
CD3/CD28 antibodies and IL-2.
Measurement of IL-2, IFNc, Granzyme B and Perforin
The amounts of murine IL-2 or IFNc in 100-mL culture
supernatants were determined by enzyme-linked immunosorbent
assay (ELISA) according to the manufacturer’s instructions (BD
Pharmingen, San Diego, CA, USA). The detection limit of the
assay was 0.04 ng/ml. The production of murine IL-2, IFNc,
granzyme B and perforin were also checked by intracellular
staining. The antibody specific for murine IL-2 was not reactive
toward the rhIL-2 in the culture.
Adoptive Immunotherapy
B16.gp33 melanoma cells. B16.gp33 melanoma cells
derived from B16 melanoma cells genetically modified to express
gene encoding amino acid 33–41 of glycoprotein from LCMV
(gp33) under the control of actin promoter were kindly provided
by Dr. Hanspeter Pircher [49]. B16.gp33 melanoma cells were
inoculated intravenously into host mice (0.5610
6 cells per mouse).
Tumor colonies with characteristic dark pigmentation formed in
the lungs after intravenous inoculation. Tumor diameter was also
measured as an index of tumor growth.
Generation of P14 CTL. P14 TCR is specific for amino acid
33–41 of the glycoprotein from LCMV (gp 33 epitope of LCMV)
in the context of H-2D
b. P14 CTL were generated by activation of
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+ T cells from the spleens as previously described [39].
P14 CD8
+ T cells (1610
5 cells/mL) were activated by KM-9
antigenic peptide (KAVTNFATM; AnaSpec, San Jose, CA)
presented by LPS-activated syngeneic B cell blasts (mitomycin C
treated; 5610
5 cells/mL), with or without rhIL-2 (5 ng/ml)
administration at 0 or 24 hours after stimulation. At the end of
the 3-day activation culture, the activated cells were washed and
cultured in the presence of rhIL-2 (5 ng/mL) for 3–4 more days.
P14 CTL adoptive immunotherapy. The P14 effectors
were injected via the tail vein in 0.15 mL of 1 X PBS into the mice
that had previously been inoculated with B16.gp33 melanoma
cells for 8 days. Control mice for the adoptive transfer received 1
X PBS or B16-F10 cells which did not express gp33 epitope of
LCMV.
Detection of Granzyme B and IFNc in Tumor-Infiltrating
Lymphocytes
At 4 hours after transfer of CFSE-labeled P14 and P14IL-2
effector cells, the lung tissue was subjected to immunohistochem-
ical staining by FITC anti-granzyme B antibody (1 mg/mL),
followed by anti-Fluorescein peroxidase. For checking IFNc
production in the lung by immunohistochemical staining, the
lung tissue was stained with anti-IFNc antibody (5 mg/mL),
followed by biotin goat anti-rat Ig (1 mg/mL) and streptavidin-
peroxidase (1:1000). After wash, the tissue was subjected to
NOVA-RED and Hematoxylin staining. In addition, the lympho-
cytes in the lung were isolated and subjected to intracellular
staining by PE anti-granzyme B or PE anti-IFNc antibody, and
analysis by flow cytometry. For isolation of lymphocytes in the
lung, lung tissues were ground with fine metal strainer, followed by
digestion with HBSS containing 5% FBS, 125 U/mL collagenase
I (GIBCO Inc., Grand Island, NY, USA), 60 U/mL DNase I and
60 U/mL hyaluronidase (Sigma, St Louis, MO, USA) for 60 min
at 37uC. After wash with HBSS for 3 times and RBC lysis, the cells
were harvested for further intracellular staining.
Statistical Analysis
Experiments were performed in triplicates for at least three
times. Data are presented as mean values6S.D. Statistical analysis
of the data was carried out using Student t test.
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